走罐法治疗寻常型银屑病血瘀证60例临床研究
|
摘要
目的:观察走罐法治疗寻常型银屑病血瘀证的有效性和安全性。方法:选取120例寻常型银屑病血瘀证患者为研究对象,按1∶1比例分为观察组和对照组各60例。观察组予走罐法治疗,对照组予以异维A酸软胶囊口服,2组均治疗8周。治疗前及治疗2、4、6、8周对2组患者进行银屑病面积和严重程度评分法(PASI)评分,评估治疗4周和治疗8周时的临床疗效,观察不良反应。结果:治疗前,2组PASI评分比较,差异无统计学意义(P> 0.05)。治疗2、4、6、8周,观察组PASI评分均低于同期对照组,差异均有统计学意义(P <0.05)。治疗4周,观察组总有效率80.00%,对照组总有效率65.00%,2组比较,差异有统计学意义(P <0.05)。治疗8周,观察组总有效率93.33%,对照组总有效率76.67%,2组比较,差异有统计学意义(P <0.05)。2组不良反应发生率比较,差异无统计学意义(P> 0.05)。结论:走罐法治疗寻常型银屑病血瘀证安全有效。
Objective: To observe the effectiveness and safety of movable cupping therapy for psoriasis vulgaris with blood-stasis syndrome. Methods: Enrolled 120 cases of patients with psoriasis vulgaris with blood-stasis syndrome as study subjects, and divided them into the observation group and the control group randomly, 60 cases in each group. The observation group received movable cupping therapy, while the control group received the oral administration of isotretinoin soft capsules. The treatment for both groups lasted for 8 weeks. Assessed the scores of psoriasis area and severity index(PASI) in both groups before treatment and after 2, 4, 6 and 8 weeks of treatment,evaluated the clinical effect after 4 and 8 weeks of treatment,and observed the adverse reactions. Results: Before treatment, comparing the scores of PASI in both groups, there was no significant difference being found(P > 0.05). After 2, 4,6 and 8 weeks of treatment, the scores of PASI in the observation group were lower than those in the control group,differences being significant(P < 0.05). After 4 weeks of treatment, the total effective rate was 80.00% in the observation group and 65.00% in the control group,difference being significant(P < 0.05). After 8 weeks of treatment, the total effective rate was 93.33% in the observation group and 76.67% in the control group, difference being significant(P < 0.05). Comparing the incidence of adverse reactions in both groups, there was no significant difference being found(P> 0.05). Conclusion: Movable cupping therapy is safe and effective to treat psoriasis vulgaris with blood-stasis syndrome.
Objective: To observe the effectiveness and safety of movable cupping therapy for psoriasis vulgaris with blood-stasis syndrome. Methods: Enrolled 120 cases of patients with psoriasis vulgaris with blood-stasis syndrome as study subjects, and divided them into the observation group and the control group randomly, 60 cases in each group. The observation group received movable cupping therapy, while the control group received the oral administration of isotretinoin soft capsules. The treatment for both groups lasted for 8 weeks. Assessed the scores of psoriasis area and severity index(PASI) in both groups before treatment and after 2, 4, 6 and 8 weeks of treatment,evaluated the clinical effect after 4 and 8 weeks of treatment,and observed the adverse reactions. Results: Before treatment, comparing the scores of PASI in both groups, there was no significant difference being found(P > 0.05). After 2, 4,6 and 8 weeks of treatment, the scores of PASI in the observation group were lower than those in the control group,differences being significant(P < 0.05). After 4 weeks of treatment, the total effective rate was 80.00% in the observation group and 65.00% in the control group,difference being significant(P < 0.05). After 8 weeks of treatment, the total effective rate was 93.33% in the observation group and 76.67% in the control group, difference being significant(P < 0.05). Comparing the incidence of adverse reactions in both groups, there was no significant difference being found(P> 0.05). Conclusion: Movable cupping therapy is safe and effective to treat psoriasis vulgaris with blood-stasis syndrome.
引文
[1]赵辨.临床皮肤病学[M].南京:江苏科学技术出版社,2003:759.
[2]国家中医药管理局.ZY/T001.8-1994中华人民共和国中医药行业标准·中医皮肤科病证诊断疗效标准[S].南京:南京大学出版社,1994:154-155.
[3]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:299-302.
[4]朱峻,徐田红,沈宏,等.197例银屑病患者血清中鳞状细胞癌抗原的表达及意义[J].中国中西医结合皮肤性病学杂志,2014,13(5):298-300.
[5] Ryan C,Kirby B.Proriasis is a disease with multiple cardio-vascular and metabolic comorbidities[J].Dermatol Clin,2015,33(1):41-55.
[6] Grozdev I, Korman N, Tsankov N.Proriasis as a systemicdisease[J].Clin Dermatol,2014,32(3):343-350.
[7]景暻,郑敏.银屑病共患疾病的临床研究进展[J].中华皮肤科杂志,2015,22(12):899-901.
[8]董亦秋,刘红霞,顾煜,等.走罐疗法配合中药治疗寻常型斑块型银屑病32例疗效观察[J].北京中医药大学学报(中医临床版),2012,19(3):25-27.
[2]国家中医药管理局.ZY/T001.8-1994中华人民共和国中医药行业标准·中医皮肤科病证诊断疗效标准[S].南京:南京大学出版社,1994:154-155.
[3]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:299-302.
[4]朱峻,徐田红,沈宏,等.197例银屑病患者血清中鳞状细胞癌抗原的表达及意义[J].中国中西医结合皮肤性病学杂志,2014,13(5):298-300.
[5] Ryan C,Kirby B.Proriasis is a disease with multiple cardio-vascular and metabolic comorbidities[J].Dermatol Clin,2015,33(1):41-55.
[6] Grozdev I, Korman N, Tsankov N.Proriasis as a systemicdisease[J].Clin Dermatol,2014,32(3):343-350.
[7]景暻,郑敏.银屑病共患疾病的临床研究进展[J].中华皮肤科杂志,2015,22(12):899-901.
[8]董亦秋,刘红霞,顾煜,等.走罐疗法配合中药治疗寻常型斑块型银屑病32例疗效观察[J].北京中医药大学学报(中医临床版),2012,19(3):25-27.